Vilight Medical Secures Over RMB 100 Million Strategic Financing to Advance Laser-Based Medical Innovation

In March 2024, Shenzhen Vivolight Medical Device & Technology Co., Ltd. (hereinafter referred to as “Vivolight”) secured strategic investment exceeding RMB 100 million. This round of financing was jointly led by Sinowisdom Capital, Guangzhou Industrial Investment Capital, and Zhuiguang Hard Tech. The funds will be utilized for the continuous development of new products in the field of laser medicine, clinical registration, and further expansion into overseas markets.

Vivolight is committed to building a leading innovative platform for laser-based medical technologies. Established in 2012, the company is a pioneer and innovation leader in China’s laser medicine sector. Its core team hails from prestigious institutions such as Tsinghua University, the Chinese Academy of Sciences, and West China Medical Center, focusing on pioneering technological innovations, independent R&D, and in-house manufacturing in the field of laser medicine. Vivolight is one of the few companies in the industry with integrated capabilities in software, hardware, and consumables development, and a rare domestic manufacturer capable of independently developing core components. Its products have demonstrated outstanding efficacy and earned high recognition from clinical experts. The company has achieved a compound annual growth rate (CAGR) of over 80% in product sales, with its flagship coronary OCT system capturing the largest market share among domestic manufacturers. Emphasizing dual advancement in diagnosis and therapy, and leveraging cutting-edge optoelectronic technologies under the philosophy of integrating medicine with engineering, Vivolight has deployed several innovative laser-based medical products across three core therapeutic areas: coronary, peripheral, and neurological conditions. Looking ahead, the company will continue to diligently build an innovative hard-tech platform for “integrated diagnosis and treatment” covering a wide range of diseases.

Regarding this round of financing,Mr. Zhu Rui, Founder of VivolightIndicates“We are deeply grateful to our investors for their recognition and support of the company. The post-pandemic era has brought greater opportunities to companies that possess innovative awareness and capabilities, as well as modern business thinking. In addition to further deepening and refining its existing coronary OCT products, Vivolight is about to launch major innovative products. The funds from this financing round will be used to accelerate technological R&D and product promotion.”

Mr. Zhu Lifeng, Head of Investment and Financing at Vivolight, stated“Vivolight’s unwavering commitment to the field of laser medicine over the past decade has enabled us to accumulate significant technological advantages, while our commercialization capabilities have been validated by the market. Through multiple rounds of financing, we have found more like-minded partners who share our vision. Together, we will forge ahead to build a leading innovative platform for laser-based medical technologies.”

Mr. Zong Peimin, founder of Sinowisdom Capital, stated“Cardiovascular diseases are the most common non-communicable diseases globally, causing 18.6 million deaths annually and accounting for one-third of all deaths worldwide. Percutaneous Coronary Intervention (PCI) is currently one of the primary treatments for cardiovascular diseases. As the intravascular imaging technology with the highest resolution, Optical Coherence Tomography (OCT) compensates for the limitations of traditional imaging methods, helping to precisely identify the causes of vascular lesions and enabling precision medicine. Vivolight’s products are not only applicable to cardiovascular conditions but also to cerebrovascular and peripheral vascular diseases, extending from diagnostic technologies to therapeutic solutions, thereby providing patients with a comprehensive dual-drive solution integrating both diagnosis and treatment. Zhejiang Sinowisdom Capital has long prioritized investments in next-generation biotechnologies, particularly high-quality sci-tech innovative enterprises like Vivolight, whose core technologies have achieved global leadership, securing its position as the number one domestic brand in the industry. We look forward to the launch of Vivolight’s increasingly diverse product portfolio in the future, aiming to establish it as a truly world-class laser medical innovation platform that makes greater contributions to human health and well-being.”

Mr. Wei Dahua, Chairman of Guangzhou Industrial Investment Capital“Guangzhou Industrial Investment Capital is the specialized platform for Guangzhou Industrial Investment Group’s comprehensive investment operations, including strategic investment, investment promotion, fund management, industrial research, and state-owned equity M&A and mixed-ownership reform. The biopharmaceutical and health sector represents a key focus area in Guangzhou Industrial Investment Capital’s portfolio. Vivolight specializes in the R&D and application of high-end medical devices, with deep engagement in the field of laser-based diagnosis and treatment, achieving independent control over core components such as detectors, data acquisition cards, and lasers. Guangzhou Industrial Investment Capital will support the company’s rapid growth through investment and facilitate the implementation of its business operations in Guangzhou. We look forward to Vivolight continuing to build a globally innovative laser medical device industry platform, providing the sector with more cutting-edge technologies and products, and leveraging the power of science and technology to benefit humanity.”

Mr. Yu Yang, Senior Vice President of Vivolight Hard Tech, stated“As China’s vast population base enters a stage of moderate to deep aging, companies in the high-end medical device sector will face new opportunities and challenges. Centralized volume-based procurement under the national medical insurance scheme has shortened the market introduction cycle and product lifecycle for medical device innovations, accelerating the elimination of participants who have failed to adapt their mindset. Vivolight boasts a strong product management team and masters core technologies in the field of laser medical devices, holding promise to become an international R&D platform for laser medical devices. We hope our investment will help the company reach new heights.”